In a preclinical study, researchers found the HDACi entinostat (ENT) increased the expression of estrogen receptor-α (ERα) and aromatase in breast cancer cells and restored the sensitization of breast cancer cells to the aromatase inhibitor letrozole both in vitro and in vivo. This evidence concerns the gene ESR1 and breast carcinoma.